Results 41 to 50 of about 47,712 (207)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin ...
Daria Ja’arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi, Murtaza M Tambuwala   +4 more
doaj   +1 more source

The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]

, 2016
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Adelhorst, Al-Sabah, Baggio, Beinborn, Biasini, Chen, Chen, Cheng, Coopman, Dan Donnelly, DeFronzo, Di Paolo, Donnelly, Drucker, Hoang, Hollenstein, Inooka, Kieffer, Knudsen, Koole, Koole, Koole, López de Maturana, López de Maturana, Mann, Mann, Mayo, Miller, Monaghan, Moon, Parthier, Perret, Pioszak, Rachel L. Dods, Roberts, Rodrigues, Runge, Runge, Sanchez, Siu, Solano, Tibaduiza, Turton, Underwood, Vertongen, Vilardaga, Wettergren, Wootten, Xiao, Yang, Ørskov   +50 more
core   +1 more source

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Diabetes, Metabolic Syndrome and Obesity, 2020
Richard A Chudleigh,1 Julia Platts,2 Stephen C Bain1,3 1Singleton Hospital, Swansea Bay University Health Board, Swansea, UK; 2Diabetes Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK; 3Diabetes Research Unit ...
Chudleigh RA, Platts J, Bain SC
doaj  

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]

, 2018
Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard, B. Gobron, D. Chappard, G. Mabilleau   +3 more
core   +3 more sources

GLP-1 Receptor Agonists and Kidney Protection

Medicina, 2019
Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR).
Eulalia Greco, Giuseppina Russo, Annalisa Giandalia, Francesca Viazzi, Roberto Pontremoli, Salvatore De Cosmo   +5 more
openaire   +3 more sources

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
A. M. Deane, Deane, Deane, Deane, M. Horowitz, Schwartz, Umpierrez   +6 more
core   +1 more source

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

The pharmacology and function of receptors for short-chain fatty acids [PDF]

, 2015
Despite some blockbuster G protein–coupled receptor (GPCR) drugs, only a small fraction (∼15%) of the more than 390 nonodorant GPCRs have been successfully targeted by the pharmaceutical industry.
Bolognini, Daniele, Milligan, Graeme, Moss, Catherine E., Tobin, Andrew B.   +3 more
core   +1 more source

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]

, 2020
Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Lingvay, Ildiko, McCrimmon, Rory, Thielke, Desirée   +6 more
core   +2 more sources

Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans [PDF]

, 2018
Purpose: Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients.
Reubi, Jean, Waser, Beatrice
core